ACRS vs. NATR, ADCT, XOMA, MRSN, NKTR, AQST, QURE, ENTA, ELYM, and EPIX
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Nature's Sunshine Products (NATR), ADC Therapeutics (ADCT), XOMA (XOMA), Mersana Therapeutics (MRSN), Nektar Therapeutics (NKTR), Aquestive Therapeutics (AQST), uniQure (QURE), Enanta Pharmaceuticals (ENTA), Eliem Therapeutics (ELYM), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical preparations" industry.
Nature's Sunshine Products (NASDAQ:NATR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
Nature's Sunshine Products has a net margin of 3.69% compared to Nature's Sunshine Products' net margin of -248.28%. Aclaris Therapeutics' return on equity of 10.59% beat Nature's Sunshine Products' return on equity.
In the previous week, Aclaris Therapeutics had 1 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 1 mentions for Aclaris Therapeutics and 0 mentions for Nature's Sunshine Products. Aclaris Therapeutics' average media sentiment score of 0.00 equaled Nature's Sunshine Products'average media sentiment score.
Nature's Sunshine Products has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
Nature's Sunshine Products currently has a consensus price target of $24.00, suggesting a potential upside of 59.57%. Aclaris Therapeutics has a consensus price target of $22.25, suggesting a potential upside of 2,102.97%. Given Nature's Sunshine Products' higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Nature's Sunshine Products.
79.4% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 4.7% of Nature's Sunshine Products shares are held by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Aclaris Therapeutics received 216 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 66.96% of users gave Aclaris Therapeutics an outperform vote while only 62.89% of users gave Nature's Sunshine Products an outperform vote.
Nature's Sunshine Products has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
Summary
Nature's Sunshine Products beats Aclaris Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
